Metastatic melanoma: chemotherapy.
暂无分享,去创建一个
S. Taillibert | M. Del Vecchio | D. Khayat | O. Rixe | C. Bernard‐Marty | E. Bajetta | R. Buzzoni | S. Aglione | M. Vitali | P. Nova
[1] R. Parker,et al. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[2] J. Lee,et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] O. Nanni,et al. Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] M. F. Aguero,et al. Bryostatin-1 and IL-2 Synergize to Induce IFN-γ Expression in Human Peripheral Blood T Cells: Implications for Cancer Immunotherapy1 , 2001, The Journal of Immunology.
[5] B. Collins,et al. Thalidomide for malignant melanoma. , 2001, The New England journal of medicine.
[6] D. Schadendorf,et al. Drug‐resistance in human melanoma , 2001, International journal of cancer.
[7] P. Frost,et al. mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. , 2001, Endocrine-related cancer.
[8] M. Pantaleo,et al. Treatment of brain metastases of malignant melanoma with temozolomide. , 2001, The New England journal of medicine.
[9] H. Kittler,et al. Cisplatin and carboplatin combination as second-line chemotherapy in dacarbazine-resistant melanoma patients , 2001, Melanoma research.
[10] S. Steinberg,et al. Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] W. Yung. Future directions for temozolomide therapy. , 2001, Seminars in oncology.
[12] D. Schwartzentruber. Guidelines for the Safe Administration of High-Dose Interleukin-2 , 2001, Journal of immunotherapy.
[13] P. Queirolo,et al. A Feasibility Study using Polychemotherapy (Cisplatin + Vindesine + Dacarbazine) plus Interferon-Alpha or Monochemotherapy with Dacarbazine plus Interferon-Alpha in Metastatic Melanoma , 2001, Tumori.
[14] M. Clay,et al. A phase II study of high dose tamoxifen and weekly cisplatin in patients with metastatic melanoma , 2001, Melanoma research.
[15] R. Mcgarry,et al. Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials , 2001, Melanoma research.
[16] P. Ascierto,et al. Cisplatin, dacarbazine, and fotemustine plus interferon α in patients with advanced malignant melanoma , 2000 .
[17] M. Bernstein,et al. Phase II Trial of Pyrazoloacridine in Children With Solid Tumors: A Pediatric Oncology Group Phase II Study , 2000, Journal of pediatric hematology/oncology.
[18] O. Larsson,et al. Tamoxifen-induced cell death in malignant melanoma cells: possible involvement of the insulin-like growth factor-1 (IGF-1) pathway , 2000, Molecular and Cellular Endocrinology.
[19] M. Atkins,et al. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. , 2000, The cancer journal from Scientific American.
[20] N. Savaraj,et al. A clinical trial of intravenous vinorelbine tartrate plus tamoxifen in the treatment of patients with advanced malignant melanoma , 2000 .
[21] A. Eggermont,et al. The Emerging Role of Cytokines in the Treatment of Advanced Melanoma , 2000, Oncology.
[22] A. Eggermont,et al. The role of interleukin-2 in the management of stage IV melanoma: the EORTC melanoma cooperative group program. , 2000, The cancer journal from Scientific American.
[23] C. Dinney,et al. Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[24] C. Begg,et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] D. Morton,et al. Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor, and tamoxifen for patients with metastatic melanoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] D. V. Von Hoff,et al. A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[27] R. Fisher,et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] K. Rowland,et al. Phase III clinical trial of the combination of cisplatin, dacarbazine, and carmustine with or without tamoxifen in patients with advanced malignant melanoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] S. Steinberg,et al. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] M. Avril,et al. Randomized trial of treatment with cisplatin and interleukin-2 either alone or in combination with interferon-alpha-2a in patients with metastatic melanoma: a Federation Nationale des Centres de Lutte Contre le Cancer Multicenter, parallel study. , 1999, Cancer.
[31] J. Richards,et al. Combination of chemotherapy with interleukin-2 and interferon alfa for the treatment of metastatic melanoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] C. Scheibenbogen,et al. Long‐term outcome of treatment with dacarbazine, cisplatin, interferon-α and intravenous high dose interleukin‐2 in poor risk melanoma patients , 1998, Melanoma research.
[33] S. Aamdal,et al. Clinical experience of fotemustine, cisplatin and high dose tamoxifen in patients with metastatic malignant melanoma , 1998, Melanoma research.
[34] M. Binder,et al. Treatment of metastatic malignant melanoma with dacarbazine plus fotemustine. , 1998, European journal of cancer.
[35] S. Steinberg,et al. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. , 1998, Annals of surgery.
[36] M. Atkins. Immunotherapy and experimental approaches for metastatic melanoma. , 1998, Hematology/oncology clinics of North America.
[37] B. Dréno,et al. Subcutaneous interleukin-2 and interferon-alpha therapy associated with cisplatin monochemotherapy in the treatment of metastatic melanoma. , 1998, European journal of dermatology : EJD.
[38] A. Buzaid,et al. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] M. Atkins,et al. Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] N. Barth,et al. Interferon-alpha and chemohormonal therapy for patients with advanced melanoma: final results of a phase I-II study of the Cancer Biotherapy Research Group and the Mid-Atlantic Oncology Program. , 1998, Cancer.
[41] J. Grob,et al. Combined treatment with dacarbazine, cisplatin, fotemustine and tamoxifen in metastatic malignant melanoma , 1998, Melanoma research.
[42] M. Weichenthal,et al. Fotemustine and interferon α2b in metastatic malignant melanoma , 1998, Journal of Cancer Research and Clinical Oncology.
[43] P. Tagliaferri,et al. Daily low-dose subcutaneous recombinant interleukin-2 by alternate weekly administration: antitumor activity and immunomodulatory effects. , 1998, American journal of clinical oncology.
[44] M. Del Vecchio,et al. Preliminary Experience with High-Dose Cisplatin, Reduced Glutathione and Natural Interferon-α in Dacarbazine-Resistant Malignant Melanoma , 1998, Tumori.
[45] F. Fiore,et al. Fotemustine and dacarbazine plus recombinant interferon alpha 2a in thetreatment of advanced melanoma. , 1997, European journal of cancer.
[46] A. Enk,et al. Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[47] M. Atkins,et al. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[48] M. Atkins,et al. The treatment of metastatic melanoma with chemotherapy and biologics. , 1997, Current opinion in oncology.
[49] A. Photiou,et al. In vitro synergy of paclitaxel (Taxol) and vinorelbine (navelbine) against human melanoma cell lines. , 1997, European journal of cancer.
[50] J. Thompson,et al. Outpatient chemoimmunotherapy for the treatment of metastatic melanoma. , 1997, Seminars in oncology.
[51] E. Maxwell,et al. Interleukin-10 inhibits tumor metastasis through an NK cell-dependent mechanism , 1996, The Journal of experimental medicine.
[52] M. Lotze,et al. Systemic administration of cellular IL-10 induces an effective, specific, and long-lived immune response against established tumors in mice. , 1996, Journal of immunology.
[53] B. Zee,et al. Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[54] P. Quaglino,et al. Low-dose integrated chemoimmunohormonotherapy with cisplatin, subcutaneous interleukin-2, interferon and tamoxifen for advanced metastatic melanoma—a pilot study , 1996, Melanoma research.
[55] J. Kirkwood,et al. Interferons in melanoma. , 1996, Current opinion in oncology.
[56] S. Retsas,et al. Taxol and vinorelbine: a new active combination for disseminated malignant melanoma , 1996, Anti-cancer drugs.
[57] D. V. Von Hoff,et al. Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[58] T. Petit,et al. Fotemustine, dacarbazine, vindesine combination chemotherapy in advanced malignant melanoma: a phase II study of 43 patients , 1995, Melanoma research.
[59] N. Savaraj,et al. Phase II Trial of Piritrexim and DTIC Using an Alternating Dose Schedule in Metastatic Melanoma , 1995, American journal of clinical oncology.
[60] A. Buzaid,et al. Systemic treatments for advanced cutaneous melanoma. , 1995, Oncology.
[61] M. Ernstoff,et al. Dacarbazine, cisplatin and carmustine, with or without tamoxifen, for metastatic melanoma: 5-year follow-up , 1995, Melanoma research.
[62] E. Bajetta,et al. Combined Carboplatin and Cytosine Arabinoside in Metastatic Melanoma Refractory to Dacarbazine , 1995, Tumori.
[63] M. Glabbeke,et al. Palliative therapy of melanoma patients with fotemustine. Inverse relationship between tumour load and treatment effectiveness. A multicentre phase II trial of the EORTC‐Melanoma Cooperative Group (MCG) , 1995, Melanoma research.
[64] S. Duensing,et al. Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-alpha after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen. , 1995, European journal of cancer.
[65] N. Bleehen,et al. Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[66] R. Fisher,et al. Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[67] R. D'Amato,et al. Thalidomide is an inhibitor of angiogenesis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[68] P. Queirolo,et al. Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[69] S. Rosenberg,et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. , 1994, JAMA.
[70] A. Buzaid,et al. Role of recombinant interleukin-2 in combination with interferon-alfa and chemotherapy in the treatment of advanced melanoma. , 1993, Seminars in oncology.
[71] S. Martino,et al. A phase II study of dacarbazine and cisplatin in combination with outpatient administered interleukin‐2 in metastatic malignant melanoma , 1993, Cancer.
[72] A. Woodcock,et al. Sequential administration of varying doses of dacarbazine and fotemustine in advanced malignant melanoma. , 1993, British Journal of Cancer.
[73] C. Boni,et al. Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen. , 1992, The New England journal of medicine.
[74] J. Richards,et al. Sequential chemoimmunotherapy in the treatment of metastatic melanoma. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[75] V. Devita,et al. Biologic Therapy of Cancer , 1992 .
[76] S. Aamdal,et al. Sequential administration of dacarbazine and fotemustine in patients with disseminated malignant melanoma--an effective combination with unexpected toxicity. , 1992, European journal of cancer.
[77] Hamblin Tj. Interleukin-2 for anti-cancer therapy. , 1991 .
[78] M. Atkins,et al. Interleukin-2 and high-dose cisplatin in patients with metastatic melanoma: a pilot study. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[79] C. Falkson,et al. Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[80] M. Aapro,et al. Multicenter phase II trial of the single agent fotemustine in patients with advanced malignant melanoma. , 1991, Annals of oncology : official journal of the European Society for Medical Oncology.
[81] M. Collier,et al. Phase II trial of piritrexim in metastatic melanoma using intermittent, low-dose administration. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[82] D. Trump,et al. A phase II study of taxol in patients with malignant melanoma , 1991, Investigational New Drugs.
[83] M. Namer,et al. Final report of the french multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases , 1990, Cancer.
[84] E. Franco. Chemotherapy of disseminated melanoma with bleomycin, vincristine, CCNU, and DTIC (BOLD regimen) , 1990, Cancer.
[85] S. Steinberg,et al. Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[86] R. Benjamin,et al. A prospective evaluation of a triple‐drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma , 1989, Cancer.
[87] W. Linehan,et al. Experience with the Use of High‐Dose Interleukin‐2 in the Treatment of 652 Cancer Patients , 1989, Annals of surgery.
[88] A. Foltz,et al. Bleomycin, vincristine, lomustine, and DTIC chemotherapy for metastatic melanoma , 1988, Cancer.
[89] S P Langdon,et al. Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. , 1987, Cancer research.
[90] D. Guerry,et al. WR-2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[91] E. Casper,et al. Phase II trial of carboplatin in advanced malignant melanoma. , 1987, Cancer treatment reports.
[92] G. Bonadonna,et al. Cytarabine and cisplatin in advanced malignant melanoma. , 1986, Cancer treatment reports.
[93] S. Rosenberg,et al. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2 , 1985, The Journal of experimental medicine.
[94] S. Prete,et al. Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma. , 1984, Cancer treatment reports.
[95] L. Baker,et al. Vindesine in patients with metastatic malignant melanoma: a Southwest Oncology Group study. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[96] E. Krementz,et al. Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma IV. Late results after complete response to chemotherapy (central oncology group protocols 7130, 7131, and 7131A) , 1984, Cancer.
[97] J. Bitran,et al. Tamoxifen in the treatment of malignant melanoma. , 1981, Cancer treatment reports.
[98] A. Huang,et al. DTIC, CCNU, bleomycin and vincristine (BOLD) in metastatic melanoma , 1980, Cancer.
[99] J. Wood,et al. Local treatment of cutaneous and subcutaneous metastatic malignant melanoma with fotemustine , 2004, Cancer Chemotherapy and Pharmacology.
[100] K. Schallreuter,et al. Positive phase II study in the treatment of advanced malignant melanoma with fotemustine , 2004, Cancer Chemotherapy and Pharmacology.
[101] Takami Sato,et al. Paclitaxel and tamoxifen , 2000, Cancer.
[102] D. Schadendorf,et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[103] Taylor Murray,et al. Cancer statistics, 1999 , 1999, CA: a cancer journal for clinicians.
[104] A. Ullrich,et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. , 1999, Cancer research.
[105] M. Del Vecchio,et al. Pilot study of subcutaneous recombinant human interleukin 12 in metastatic melanoma. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[106] G. Trinchieri. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. , 1995, Annual review of immunology.
[107] J. Folkman. Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.
[108] S. Aamdal,et al. Activity and unexpected lung toxicity of the sequential administration of two alkylating agents--dacarbazine and fotemustine--in patients with melanoma. , 1993, European journal of cancer.
[109] C. Tangen,et al. A Southwest Oncology Group study , 1993 .
[110] M. Avril,et al. Fotemustine plus dacarbazine for malignant melanoma. , 1992, European journal of cancer.
[111] V. Devita,et al. Cancer : Principles and Practice of Oncology , 1982 .